Kim Jones: Cisplatin And Ototoxicity – The Hidden Impact on Hearing
Kim Jones, CEO and Founder at Testicular Cancer Awareness Foundation, shared a post on LinkedIn:
“Cisplatin And Ototoxicity: The Hidden Impact On Hearing
Testicular cancer can affect men at any age, and many go on to live long, healthy lives after treatment. However, the impact of cisplatin-induced hearing loss can last well beyond cancer treatment.
Hearing loss can severely affect a patient’s quality of life, leading to challenges in communication, career limitations, and social isolation. The difficulty in hearing normal conversations or enjoying day-to-day activities can be emotionally taxing and hinder overall well-being.
We are most grateful for Fennec Pharmaceuticals for addressing this unmet need. Fennec Pharmaceuticals developed Pedmark, the first and only FDA-approved sodium thiosulfate (STS) formulation designed to help prevent cisplatin-induced hearing loss.
Approved for adolescents and young adults by the FDA, PEDMARK is also recommended by the NCCN guidelines for patients aged 15–39 but can be administered to older adults as well.
This marks a significant step forward in preserving the quality of life for cancer patients.
Click here to learn more.”
Read more about Testicular Cancer on oncodaily.com.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023